Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors

Published:2020-06-11 Issue:9 Volume:86 Page:1769-1777
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Peer Cody J.¹^ORCID,Goldstein Daniel A.²,Goodell Jennifer C.¹,Nguyen Ryan¹,Figg William D.¹,Ratain Mark J.³

Affiliation:

1. Clinical Pharmacology Program National Cancer Institute Bethesda MD USA

2. Davidoff Cancer Center Rabin Medical Center Israel

3. Department of Medicine, Center for Personalized Therapeutics, and Comprehensive Cancer Center The University of Chicago Chicago IL USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14369

Reference71 articles.

1. CTLA-4 and PD-1 Pathways

2. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways

3. Checkpoint inhibitors;Heinzerling L;Dtsch Arztebl Int,2019

4. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

5. Overview of Therapeutic Drug Monitoring

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-throughput, low-cost quantification of 11 therapeutic antibodies using caprylic acid precipitation and LC-MS/MS;Analytica Chimica Acta;2024-07

2. High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer;Molecular & Cellular Proteomics;2024-05

3. Optimizing the doses of cancer drugs after usual dose finding;Clinical Trials;2023-12-27

4. Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges;Frontiers in Pharmacology;2023-11-23

5. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?;European Journal of Cancer;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3